These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25882531)

  • 1. Discovery of DS-5272 as a promising candidate: A potent and orally active p53-MDM2 interaction inhibitor.
    Miyazaki M; Uoto K; Sugimoto Y; Naito H; Yoshida K; Okayama T; Kawato H; Miyazaki M; Kitagawa M; Seki T; Fukutake S; Aonuma M; Soga T
    Bioorg Med Chem; 2015 May; 23(10):2360-7. PubMed ID: 25882531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and evaluation of novel orally active p53-MDM2 interaction inhibitors.
    Miyazaki M; Naito H; Sugimoto Y; Yoshida K; Kawato H; Okayama T; Shimizu H; Miyazaki M; Kitagawa M; Seki T; Fukutake S; Shiose Y; Aonuma M; Soga T
    Bioorg Med Chem; 2013 Jul; 21(14):4319-31. PubMed ID: 23685175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
    Zhuang C; Miao Z; Zhu L; Dong G; Guo Z; Wang S; Zhang Y; Wu Y; Yao J; Sheng C; Zhang W
    J Med Chem; 2012 Nov; 55(22):9630-42. PubMed ID: 23046248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lead optimization of novel p53-MDM2 interaction inhibitors possessing dihydroimidazothiazole scaffold.
    Miyazaki M; Naito H; Sugimoto Y; Kawato H; Okayama T; Shimizu H; Miyazaki M; Kitagawa M; Seki T; Fukutake S; Aonuma M; Soga T
    Bioorg Med Chem Lett; 2013 Feb; 23(3):728-32. PubMed ID: 23266121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.
    Gonzalez AZ; Li Z; Beck HP; Canon J; Chen A; Chow D; Duquette J; Eksterowicz J; Fox BM; Fu J; Huang X; Houze J; Jin L; Li Y; Ling Y; Lo MC; Long AM; McGee LR; McIntosh J; Oliner JD; Osgood T; Rew Y; Saiki AY; Shaffer P; Wortman S; Yakowec P; Yan X; Ye Q; Yu D; Zhao X; Zhou J; Olson SH; Sun D; Medina JC
    J Med Chem; 2014 Apr; 57(7):2963-88. PubMed ID: 24601644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of AM-7209, a potent and selective 4-amidobenzoic acid inhibitor of the MDM2-p53 interaction.
    Rew Y; Sun D; Yan X; Beck HP; Canon J; Chen A; Duquette J; Eksterowicz J; Fox BM; Fu J; Gonzalez AZ; Houze J; Huang X; Jiang M; Jin L; Li Y; Li Z; Ling Y; Lo MC; Long AM; McGee LR; McIntosh J; Oliner JD; Osgood T; Saiki AY; Shaffer P; Wang YC; Wortman S; Yakowec P; Ye Q; Yu D; Zhao X; Zhou J; Medina JC; Olson SH
    J Med Chem; 2014 Dec; 57(24):10499-511. PubMed ID: 25384157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel dihydroimidazothiazole derivatives as p53-MDM2 protein-protein interaction inhibitors: synthesis, biological evaluation and structure-activity relationships.
    Miyazaki M; Kawato H; Naito H; Ikeda M; Miyazaki M; Kitagawa M; Seki T; Fukutake S; Aonuma M; Soga T
    Bioorg Med Chem Lett; 2012 Oct; 22(20):6338-42. PubMed ID: 22995624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
    Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
    J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective and potent morpholinone inhibitors of the MDM2-p53 protein-protein interaction.
    Gonzalez AZ; Eksterowicz J; Bartberger MD; Beck HP; Canon J; Chen A; Chow D; Duquette J; Fox BM; Fu J; Huang X; Houze JB; Jin L; Li Y; Li Z; Ling Y; Lo MC; Long AM; McGee LR; McIntosh J; McMinn DL; Oliner JD; Osgood T; Rew Y; Saiki AY; Shaffer P; Wortman S; Yakowec P; Yan X; Ye Q; Yu D; Zhao X; Zhou J; Olson SH; Medina JC; Sun D
    J Med Chem; 2014 Mar; 57(6):2472-88. PubMed ID: 24548297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational design and binding mode duality of MDM2-p53 inhibitors.
    Gonzalez-Lopez de Turiso F; Sun D; Rew Y; Bartberger MD; Beck HP; Canon J; Chen A; Chow D; Correll TL; Huang X; Julian LD; Kayser F; Lo MC; Long AM; McMinn D; Oliner JD; Osgood T; Powers JP; Saiki AY; Schneider S; Shaffer P; Xiao SH; Yakowec P; Yan X; Ye Q; Yu D; Zhao X; Zhou J; Medina JC; Olson SH
    J Med Chem; 2013 May; 56(10):4053-70. PubMed ID: 23597064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein-Protein Interaction.
    Chessari G; Hardcastle IR; Ahn JS; Anil B; Anscombe E; Bawn RH; Bevan LD; Blackburn TJ; Buck I; Cano C; Carbain B; Castro J; Cons B; Cully SJ; Endicott JA; Fazal L; Golding BT; Griffin RJ; Haggerty K; Harnor SJ; Hearn K; Hobson S; Holvey RS; Howard S; Jennings CE; Johnson CN; Lunec J; Miller DC; Newell DR; Noble MEM; Reeks J; Revill CH; Riedinger C; St Denis JD; Tamanini E; Thomas H; Thompson NT; Vinković M; Wedge SR; Williams PA; Wilsher NE; Zhang B; Zhao Y
    J Med Chem; 2021 Apr; 64(7):4071-4088. PubMed ID: 33761253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based design of novel inhibitors of the MDM2-p53 interaction.
    Rew Y; Sun D; Gonzalez-Lopez De Turiso F; Bartberger MD; Beck HP; Canon J; Chen A; Chow D; Deignan J; Fox BM; Gustin D; Huang X; Jiang M; Jiao X; Jin L; Kayser F; Kopecky DJ; Li Y; Lo MC; Long AM; Michelsen K; Oliner JD; Osgood T; Ragains M; Saiki AY; Schneider S; Toteva M; Yakowec P; Yan X; Ye Q; Yu D; Zhao X; Zhou J; Medina JC; Olson SH
    J Med Chem; 2012 Jun; 55(11):4936-54. PubMed ID: 22524527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction.
    Yu S; Qin D; Shangary S; Chen J; Wang G; Ding K; McEachern D; Qiu S; Nikolovska-Coleska Z; Miller R; Kang S; Yang D; Wang S
    J Med Chem; 2009 Dec; 52(24):7970-3. PubMed ID: 19928922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development.
    Sun D; Li Z; Rew Y; Gribble M; Bartberger MD; Beck HP; Canon J; Chen A; Chen X; Chow D; Deignan J; Duquette J; Eksterowicz J; Fisher B; Fox BM; Fu J; Gonzalez AZ; Gonzalez-Lopez De Turiso F; Houze JB; Huang X; Jiang M; Jin L; Kayser F; Liu JJ; Lo MC; Long AM; Lucas B; McGee LR; McIntosh J; Mihalic J; Oliner JD; Osgood T; Peterson ML; Roveto P; Saiki AY; Shaffer P; Toteva M; Wang Y; Wang YC; Wortman S; Yakowec P; Yan X; Ye Q; Yu D; Yu M; Zhao X; Zhou J; Zhu J; Olson SH; Medina JC
    J Med Chem; 2014 Feb; 57(4):1454-72. PubMed ID: 24456472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction.
    Vaupel A; Bold G; De Pover A; Stachyra-Valat T; Lisztwan JH; Kallen J; Masuya K; Furet P
    Bioorg Med Chem Lett; 2014 May; 24(9):2110-4. PubMed ID: 24704029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.
    Ding Q; Zhang Z; Liu JJ; Jiang N; Zhang J; Ross TM; Chu XJ; Bartkovitz D; Podlaski F; Janson C; Tovar C; Filipovic ZM; Higgins B; Glenn K; Packman K; Vassilev LT; Graves B
    J Med Chem; 2013 Jul; 56(14):5979-83. PubMed ID: 23808545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Novel p53-MDM2 Inhibitor (RG7388)-Conjugated Platinum
    Liu W; Ma Y; He Y; Liu Y; Guo Z; He J; Han X; Hu Y; Li M; Jiang R; Wang S
    J Med Chem; 2024 Jun; 67(11):9645-9661. PubMed ID: 38776419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 1.
    Wang W; Shangguan S; Qiu N; Hu C; Zhang L; Hu Y
    Bioorg Med Chem; 2013 Jun; 21(11):2879-85. PubMed ID: 23601819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold.
    Hardcastle IR; Ahmed SU; Atkins H; Farnie G; Golding BT; Griffin RJ; Guyenne S; Hutton C; Källblad P; Kemp SJ; Kitching MS; Newell DR; Norbedo S; Northen JS; Reid RJ; Saravanan K; Willems HM; Lunec J
    J Med Chem; 2006 Oct; 49(21):6209-21. PubMed ID: 17034127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.
    Zheng GH; Shen JJ; Zhan YC; Yi H; Xue ST; Wang Z; Ji XY; Li ZR
    Eur J Med Chem; 2014 Jun; 81():277-88. PubMed ID: 24852275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.